Rozalina G McCoy1,2,3, Hayley J Dykhoff2,3, Lindsey Sangaralingham2,3, Joseph S Ross4,5,6,7, Pinar Karaca-Mandic8,9, Victor M Montori10,11, Nilay D Shah2,3,12. 1. Division of Community Internal Medicine, Department of Medicine, Mayo Clinic, Rochester, Minnesota. 2. Division of Health Care Policy and Research, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota. 3. Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Rochester, Minnesota. 4. National Clinician Scholars Program, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut. 5. Section of General Internal Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut. 6. Department of Health Policy and Management, Yale School of Medicine, New Haven, Connecticut. 7. Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, Connecticut. 8. Carlson School of Management, University of Minnesota, Minneapolis, Minnesota. 9. National Bureau of Economic Research, Cambridge, Massachusetts. 10. Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Department of Medicine, Mayo Clinic, Rochester, Minnesota. 11. Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester, Minnesota. 12. OptumLabs, Cambridge, Massachusetts.
Abstract
Background: High-quality diabetes care is evidence-based, timely, and equitable. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are the most recently approved class of glucose-lowering medications with additional cardio- and renal-protective benefits and low risk of hypoglycemia. Cardiovascular and kidney disease are among the most common chronic diabetes complications, whereas hypoglycemia is the most prevalent adverse effect of glucose-lowering therapy. We examine the sociodemographic and clinical factors associated with early SGLT2i initiation and appropriateness of use based on contemporaneous scientific evidence. Materials and Methods: Retrospective analysis of medical and pharmacy claims data from OptumLabs® Data Warehouse for commercially insured and Medicare Advantage adult beneficiaries with diabetes types 1 and 2, who filled any glucose-lowering medication between January 1, 2013 and December 31, 2016. Demographic (age, sex, race, income), clinical (comorbidities), and insurance-related factors affecting first prescription for a SGLT2i were examined using multivariable logistic regression. Results: Among 1,054,727 adults with pharmacologically treated diabetes, 7.2% (n = 75,500) initiated a SGLT2i. Patients with prior myocardial infarction (MI) (odds ratio [OR]: 0.94, 95% confidence interval [CI]: 0.91-0.96), heart failure (HF) (OR: 0.93, 95% CI: 0.91-0.94), kidney disease (OR: 0.80, 95% CI: 0.78-0.81), and severe hypoglycemia (OR: 0.96, 95% CI: 0.94-0.98) were all less likely to start a SGLT2i; P < 0.001 for all. SGLT2i were also less likely to be started by patients ≥75 years (OR: 0.57, 95% CI: 0.55-0.59, vs. 18-44 years), Black patients (OR: 0.93, 95% CI: 0.91-0.95, vs. White), and those with Medicare Advantage insurance (OR: 0.63, 95% CI: 0.62-0.64, vs. commercial). Conclusions: Younger, healthier, non-Black patients with commercial health insurance were most likely to start taking SGLT2i. Patients with MI, HF, kidney disease, and prior hypoglycemia were less likely to use SGLT2i, despite evidence supporting their preferential use in these patients. Efforts to address this treatment-risk paradox may help improve health outcomes among patients with type 2 diabetes.
Background: High-quality diabetes care is evidence-based, timely, and equitable. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are the most recently approved class of glucose-lowering medications with additional cardio- and renal-protective benefits and low risk of hypoglycemia. Cardiovascular and kidney disease are among the most common chronic diabetes complications, whereas hypoglycemia is the most prevalent adverse effect of glucose-lowering therapy. We examine the sociodemographic and clinical factors associated with early SGLT2i initiation and appropriateness of use based on contemporaneous scientific evidence. Materials and Methods: Retrospective analysis of medical and pharmacy claims data from OptumLabs® Data Warehouse for commercially insured and Medicare Advantage adult beneficiaries with diabetes types 1 and 2, who filled any glucose-lowering medication between January 1, 2013 and December 31, 2016. Demographic (age, sex, race, income), clinical (comorbidities), and insurance-related factors affecting first prescription for a SGLT2i were examined using multivariable logistic regression. Results: Among 1,054,727 adults with pharmacologically treated diabetes, 7.2% (n = 75,500) initiated a SGLT2i. Patients with prior myocardial infarction (MI) (odds ratio [OR]: 0.94, 95% confidence interval [CI]: 0.91-0.96), heart failure (HF) (OR: 0.93, 95% CI: 0.91-0.94), kidney disease (OR: 0.80, 95% CI: 0.78-0.81), and severe hypoglycemia (OR: 0.96, 95% CI: 0.94-0.98) were all less likely to start a SGLT2i; P < 0.001 for all. SGLT2i were also less likely to be started by patients ≥75 years (OR: 0.57, 95% CI: 0.55-0.59, vs. 18-44 years), Black patients (OR: 0.93, 95% CI: 0.91-0.95, vs. White), and those with Medicare Advantage insurance (OR: 0.63, 95% CI: 0.62-0.64, vs. commercial). Conclusions: Younger, healthier, non-Black patients with commercial health insurance were most likely to start taking SGLT2i. Patients with MI, HF, kidney disease, and prior hypoglycemia were less likely to use SGLT2i, despite evidence supporting their preferential use in these patients. Efforts to address this treatment-risk paradox may help improve health outcomes among patients with type 2 diabetes.
Authors: Alan J Garber; Martin J Abrahamson; Joshua I Barzilay; Lawrence Blonde; Zachary T Bloomgarden; Michael A Bush; Samuel Dagogo-Jack; Ralph A DeFronzo; Daniel Einhorn; Vivian A Fonseca; Jeffrey R Garber; W Timothy Garvey; George Grunberger; Yehuda Handelsman; Robert R Henry; Irl B Hirsch; Paul S Jellinger; Janet B McGill; Jeffrey I Mechanick; Paul D Rosenblit; Guillermo E Umpierrez Journal: Endocr Pract Date: 2016-01 Impact factor: 3.443
Authors: Junling Wang; Ilene H Zuckerman; Nancy A Miller; Fadia T Shaya; Jason M Noel; C Daniel Mullins Journal: Health Serv Res Date: 2007-08 Impact factor: 3.402
Authors: Alan J Garber; Martin J Abrahamson; Joshua I Barzilay; Lawrence Blonde; Zachary T Bloomgarden; Michael A Bush; Samuel Dagogo-Jack; Ralph A DeFronzo; Daniel Einhorn; Vivian A Fonseca; Jeffrey R Garber; W Timothy Garvey; George Grunberger; Yehuda Handelsman; Irl B Hirsch; Paul S Jellinger; Janet B McGill; Jeffrey I Mechanick; Paul D Rosenblit; Guillermo E Umpierrez Journal: Endocr Pract Date: 2019-01 Impact factor: 3.443
Authors: Seth A Berkowitz; Alexis A Krumme; Jerry Avorn; Troyen Brennan; Olga S Matlin; Claire M Spettell; Edmund J Pezalla; Gregory Brill; William H Shrank; Niteesh K Choudhry Journal: JAMA Intern Med Date: 2014-12 Impact factor: 21.873
Authors: Bruce Neal; Vlado Perkovic; Kenneth W Mahaffey; Dick de Zeeuw; Greg Fulcher; Ngozi Erondu; Wayne Shaw; Gordon Law; Mehul Desai; David R Matthews Journal: N Engl J Med Date: 2017-06-12 Impact factor: 91.245
Authors: Christoph Wanner; Silvio E Inzucchi; John M Lachin; David Fitchett; Maximilian von Eynatten; Michaela Mattheus; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Bernard Zinman Journal: N Engl J Med Date: 2016-06-14 Impact factor: 91.245
Authors: Arthur T Sands; Brian P Zambrowicz; Julio Rosenstock; Pablo Lapuerta; Bruce W Bode; Satish K Garg; John B Buse; Phillip Banks; Rubina Heptulla; Marc Rendell; William T Cefalu; Paul Strumph Journal: Diabetes Care Date: 2015-06-06 Impact factor: 19.112
Authors: John P Bilezikian; Nelson B Watts; Keith Usiskin; David Polidori; Albert Fung; Daniel Sullivan; Norm Rosenthal Journal: J Clin Endocrinol Metab Date: 2015-11-18 Impact factor: 5.958
Authors: Hsien-Yen Chang; Jonathan P Weiner; Thomas M Richards; Sara N Bleich; Jodi B Segal Journal: Am J Manag Care Date: 2012-11 Impact factor: 2.229
Authors: Andrew Sumarsono; Leo F Buckley; Sara R Machado; Rishi K Wadhera; Haider J Warraich; Rishi J Desai; Brendan M Everett; Darren K McGuire; Gregg C Fonarow; Javed Butler; Ambarish Pandey; Muthiah Vaduganathan Journal: Diabetes Care Date: 2020-09-04 Impact factor: 19.112
Authors: Rozalina G McCoy; Holly K Van Houten; Pinar Karaca-Mandic; Joseph S Ross; Victor M Montori; Nilay D Shah Journal: Diabetes Care Date: 2021-08-04 Impact factor: 17.152